环己烯,3-氟-4-(甲硫基)-,反-(9CI) | 137694-16-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 蝶啶及其衍生物
• 中文名称: 环己烯,3-氟-4-(甲硫基)-,反-(9CI)
• 中文别名: 1-[[2,7-二[(2R,6S)-2,6-二甲基吗啉-4-基]-6-苯基蝶啶-4-基]-(2-羟基乙基)氨基]-2-甲基丙烷-2-醇
• 英文名称: 1-[[2,7-bis[(2S,6R)-2,6-dimethylmorpholin-4-yl]-6-phenylpteridin-4-yl]-(2-hydroxyethyl)amino]-2-methylpropan-2-ol
• CAS: 137694-16-7
• 化学式: C₃₀H₄₃N₇O₄
• 分子量: 565.7
• InChiKey: JNHIGDFEPXMPAO-COPRSSIGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  41
• 可旋转键数：
  8
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  120
• 氢给体数：
  2
• 氢受体数：
  11

文献信息

• Use of CNS penetrating anticancer compounds for the treatment of protozan diseases
  申请人：Dormeyer, Matthias

  公开号：EP1808173A1

  公开（公告）日：2007-07-18

  The present invention relates to the treatment of protozoal diseases by administering cytotoxic and/or cytostatic compounds, in particular those used in anticancer therapy, to patients. In particular, the invention relates to the use of anticancer agents that can penetrate into the CNS for treatment of late stage African sleeping sickness or cerebral malaria.

  本发明涉及通过向患者施用细胞毒性和/或细胞抑制化合物，特别是用于抗癌治疗的化合物来治疗原生动物疾病。特别是，本发明涉及使用可渗透到中枢神经系统的抗癌剂来治疗晚期非洲昏睡病或脑疟疾。
• MEDICAL IMPLANTS WITH A COMBINATION OF COMPOUNDS
  申请人：Angiotech Pharmaceuticals, Inc.

  公开号：EP2101779A1

  公开（公告）日：2009-09-23
• TREATMENTS OF B-CELL PROLIFERATIVE DISORDERS
  申请人：Rickles Richard

  公开号：US20090053168A1

  公开（公告）日：2009-02-26

  The invention provides compositions and methods for the treatment of B-cell proliferative disorders that employ an A2A receptor agonist or one or more PDE inhibitors. The methods and compositions may further include an antiproliferative compound.
• COMBINATIONS FOR THE TREATMENT OF B-CELL PROLIFERATIVE DISORDERS
  申请人：Rickles Richard

  公开号：US20090047243A1

  公开（公告）日：2009-02-19

  The invention features compositions and methods employing combinations of an A2A receptor agonist and a PDE inhibitor for the treatment of a B-cell proliferative disorder, e.g., multiple myeloma.
• USE OF CNS PENETRATING ANTICANCER COMPOUNDS FOR THE TREATMENT OF PROTOZOAL DISEASES
  申请人：Dormeyer Matthias

  公开号：US20110118199A1

  公开（公告）日：2011-05-19

  The present invention relates to the treatment of protozoal diseases by administering cytotoxic and/or cytostatic compounds, in particular those used in anticancer therapy, to patients. In particular, the invention relates to the use of anticancer agents that can penetrate into the CNS for treatment of late stage African sleeping sickness or cerebral malaria.